ABBV ABBV アッヴィ

 ABBVのチャート


 ABBVの企業情報

symbol ABBV
会社名 AbbVie Inc (ABBV アッヴィ)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 アッヴィ(AbbVie Inc.)は研究型バイオ医薬品会社である。同社は各種医薬品の発見・開発・製造・販売に従事する。同社の製品はリウマチ学、胃腸病学と皮膚科学等の慢性自己免疫疾患、血液癌を含む腫瘍学、C型肝炎ウイルス(HCV)とヒト免疫不全ウイルス(HIV)を含むウイルス学、パーキンソン病と多発性硬化症等の神経学的障害、甲状腺疾患と嚢胞性線維症関連合併症を含む代謝性疾患、並びに他の健康状態の治療のために使用される。同社はHUMIRA(アダリムマブ)、腫瘍学製品、ウイルス学、追加のウイルス学製品、代謝またはホルモン製品、内分泌学製品、並びにDuopaおよびDuodopa(カルビドパおよびレボドパ)、麻酔薬およびZINBRYTA(ダクリズマブ)を含む他の製品を提供する。  アッヴィは米国の研究開発型バイオ医薬品企業。主にC型肝炎、神経学、免疫学、腫瘍学、慢性腎疾患および女性の疾患などの分野における医薬品の開発に取り組む。アボット・ラボラトリ―ズの研究開発医薬品部門の分離独立に伴い2013年度に設立。主力製品はリウマチ性関節炎や乾癬治療薬「ヒュミラ」など。本社はイリノイ州ノ―ス・シカゴ。  AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
本社所在地 847 932-7900
代表者氏名 Richard A. Gonzalez
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 847-932-7900
設立年月日 41000
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 30000人
url www.abbvie.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 9148.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 119125.30000
売上高 売上高(百万ドル) 32753.00000
企業価値(EV) 企業価値(EV)(百万ドル) 151374.30000
当期純利益 当期純利益(百万ドル) 5743.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 AbbVie Inc revenues increased 16% to $32.75B. Net income applicable to common stockholders excluding extraordinary items increased 1% to $5.74B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Research and development - Balanci increase from $4.82B to $10.16B (expense) Selling.

 ABBVのテクニカル分析


 ABBVのニュース

   Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AbbVie and Twitter and Encourages Investors to Contact the Firm  2022/04/18 01:00:00 GlobeNewswire
NEW YORK, April 17, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of AbbVie, Inc. (NYSE: ABBV) and Twitter, Inc. (NYSE: TWTR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
   Gastrointestinal Diseases Therapeutics Market to record USD 22.82 Bn growth | Evolving Opportunities with Abbott Laboratories and AbbVie Inc. | Technavio  2022/04/15 10:45:00 PR Newswire
NEW YORK, April 15, 2022 /PRNewswire/ -- The global gastrointestinal diseases therapeutics market size is expected to increase by USD 22.82 billion between 2019 and 2024, and the growth momentum is expected to accelerate at a CAGR of 9% during the forecast period. The report provides a…
   Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight  2022/04/14 17:00:00 Benzinga
Las Vegas, USA, April 14, 2022 (GLOBE NEWSWIRE) -- Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight Small-cell Lung Cancer Pipeline constitutes 100+ key companies continuously working towards developing 100+ Small-cell Lung Cancer treatment therapies, analyzes DelveInsight DelveInsight''s Small-cell Lung Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Small-cell Lung Cancer pipeline domain. Some of the essential takeaways from the Small-cell Lung Cancer Pipeline report: DelveInsight''s Small-cell Lung Cancer Pipeline analysis depicts a robust space with 100+ active players working to develop 100+ Small-cell Lung Cancer treatment pipeline therapies. Some of the key Small-cell Lung Cancer companies proactively working to develop potential drug candidates to improve the Small-cell Lung Cancer treatment scenario include Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee''s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, Mologen, Cybrexa Therapeutics, and many others.
   AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study  2022/04/14 10:09:00 Benzinga
Genmab A/S (NASDAQ: GMAB ) and AbbVie Inc (NYSE: ABBV ) announced topline results from the first cohort of the EPCORE NHL-1 phase 1/2 trial of epcoritamab (DuoBody-CD3xCD20). Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab''s DuoBody technology designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. The study cohort … Full story available on Benzinga.com
   US stock market closes higher, Dow Jones gains 1.01%  2022/04/14 03:21:49 InstaForex
At the close on the New York Stock Exchange, the Dow Jones rose 1.01%, the S&P 500 index rose 1.12%, the NASDAQ Composite index rose 2.03%. The leading gainer among the components of the Dow Jones index today was Boeing Co, which gained 6.59 points or 3.74% to close at 182.87. Walmart Inc rose 3.99 points or 2.60% to close at 157.22. American Express Company rose 4.05 points or 2.31% to close at 179.59. The biggest losers were JPMorgan Chase & Co, which shed 4.24 points or 3.22% to end the session at 127.30. The Travelers Companies Inc rose 1.23 points (0.67%) to close at 183.71, while 3M Company gained 0.08 points (0.05%) to close at 148. .66. Leading gainers among the S&P 500 index components in today''s trading were American Airlines Group, which rose 10.62% to 18.95, Gap Inc, which gained 8.23% to close at 14.46, and shares of Host Hotels & Resorts Inc, which rose 8.12% to end the session at 19.70. The biggest losers were AbbVie Inc, which shed 4.19% to close at 158.95. PayPal Holdings Inc fell 2.85% to 105.17.
   AbbVie (NYSE:ABBV) Coverage Initiated by Analysts at Wells Fargo & Company  2021/12/09 10:02:46 Dakota Financial News
Wells Fargo & Company initiated coverage on shares of AbbVie (NYSE:ABBV) in a research report released on Wednesday morning, The Fly reports. The brokerage issued an overweight rating on the stock. Several other brokerages also recently weighed in on ABBV. Barclays upped their target price on shares of AbbVie from $112.00 to $118.00 and gave []
   Direct Relief grants $277K to install solar panels in Guanicas Fire Station  2021/12/09 09:02:00 News is my Business
Nonprofit organization Direct Relief inaugurated a $277,000 solar energy project in Guánicas Fire Station, through a grant from biopharmaceutical company AbbVie, which donated $50 million for these types of projects. The project will allow for these first responders to continue serving the people even in the event of natural disasters that may affect primary services, []
   Abbvie Inc (ABBV) EVP, Chief HR Officer Timothy J. Richmond Sold $6 million of Shares  2021/12/08 22:15:02 GuruFocus
Related Stocks: ABBV ,
   AbbVie unit to pay $200 million to resolve closely watched opioid lawsuit in New York - STAT  2021/12/08 21:58:34 STAT News
Allergan will pay up to $200 million to resolve allegations made by New York state and two counties that it helped fuel the opioid crisis.
   Morris Capital Advisors LLC Sells 1,065 Shares of AbbVie Inc. (NYSE:ABBV)  2021/12/08 20:08:42 Dakota Financial News
Morris Capital Advisors LLC cut its stake in AbbVie Inc. (NYSE:ABBV) by 4.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,454 shares of the companys stock after selling 1,065 shares during the quarter. AbbVie comprises about 2.2% of Morris Capital Advisors LLCs []
   Landaas & Co. WI ADV Sells 100 Shares of AbbVie Inc. (NYSE:ABBV)  2021/11/05 23:54:41 Transcript Daily
Landaas & Co. WI ADV lowered its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,479 shares of the companys stock after selling 100 shares during the period. AbbVie comprises approximately 0.3% []
   Fort Sheridan Advisors LLC Increases Stock Holdings in AbbVie Inc. (NYSE:ABBV)  2021/11/05 23:14:41 Dakota Financial News
Fort Sheridan Advisors LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 7.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,822 shares of the companys stock after purchasing an additional 1,330 shares during the period. Fort Sheridan Advisors []
   Westshore Wealth LLC Increases Holdings in AbbVie Inc. (NYSE:ABBV)  2021/11/05 19:36:43 Transcript Daily
Westshore Wealth LLC grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 7.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,026 shares of the companys stock after purchasing an additional 600 shares during the quarter. Westshore Wealth LLCs []
   Man Group plc Has $34.29 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV)  2021/11/05 17:22:43 Transcript Daily
Man Group plc lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 27.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 304,427 shares of the companys stock after selling 117,301 shares during the period. Man Group plcs holdings in AbbVie were worth $34,290,000 as of its []

 関連キーワード  (医薬品 米国株 ABBV アッヴィ ABBV )

 twitter  (公式ツイッターやCEOツイッターなど)